FY2026 EPS Estimates for AbbVie Cut by Erste Group Bank

AbbVie Inc. (NYSE:ABBV) – Stock analysts at Erste Group Bank dropped their FY2026 EPS estimates for AbbVie in a research report issued on Wednesday, July 15th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings per share of $14.08 for the year, down from their previous estimate of $14.23. The consensus estimate for AbbVie’s current full-year earnings is $14.16 per share.

ABBV has been the topic of a number of other reports. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Citigroup boosted their price target on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday. HSBC restated a “buy” rating and issued a $300.00 price objective on shares of AbbVie in a research note on Monday, July 6th. Guggenheim raised their price objective on AbbVie from $249.00 to $261.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $267.67.

AbbVie Price Performance

Shares of ABBV opened at $254.53 on Friday. The company has a market cap of $449.70 billion, a PE ratio of 125.38, a price-to-earnings-growth ratio of 0.84 and a beta of 0.30. The firm has a 50-day moving average of $229.80 and a 200-day moving average of $221.94. AbbVie has a one year low of $184.63 and a one year high of $261.64.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.46 earnings per share.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Procyon Advisors LLC lifted its stake in shares of AbbVie by 19.9% in the fourth quarter. Procyon Advisors LLC now owns 32,752 shares of the company’s stock valued at $7,484,000 after buying an additional 5,427 shares in the last quarter. Waycross Partners LLC increased its position in shares of AbbVie by 2.9% during the fourth quarter. Waycross Partners LLC now owns 182,476 shares of the company’s stock worth $41,694,000 after acquiring an additional 5,063 shares in the last quarter. Calamos Advisors LLC raised its holdings in shares of AbbVie by 3.4% in the 4th quarter. Calamos Advisors LLC now owns 466,290 shares of the company’s stock worth $106,543,000 after acquiring an additional 15,458 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in AbbVie by 11.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 636,710 shares of the company’s stock valued at $143,026,000 after acquiring an additional 66,720 shares in the last quarter. Finally, Savvy Advisors Inc. boosted its stake in AbbVie by 22.2% during the 4th quarter. Savvy Advisors Inc. now owns 36,568 shares of the company’s stock valued at $8,355,000 after purchasing an additional 6,646 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio is 340.89%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Allergan Aesthetics unit won European Commission approval for Boey® (trenibotulinumtoxinE), a new facial injectable for glabellar lines. The approval gives AbbVie a differentiated aesthetics product in all 30 EEA countries and could add another growth driver to offset Humira-related declines. Article Title
• Positive Sentiment: Investors are also focusing on AbbVie’s neuroscience franchise and other newer product catalysts, with analysts expecting solid Q2 growth and continued momentum from brands such as Vyalev, RINVOQ, and SKYRIZI ahead of earnings. Article Title
• Positive Sentiment: Brokerage sentiment remains constructive, with recent coverage showing a “Moderate Buy” consensus and multiple price-target increases in July, reinforcing confidence in AbbVie’s long-term pipeline and earnings outlook. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for AbbVie to $14.08 from $14.23, though the new estimate remains close to the consensus of $14.18 and is not a major deviation. Article Title

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.